27 results about "Equol" patented technology

The invention discloses a dihydrodaidzein reductase, a combinatorial enzyme and an application of the dihydrodaidzein reductase and the combinatorial enzyme in synthesis of S-equol. The dihydrodaidzein reductase is a mutant which takes the dihydrodaidzein reductase AeDHDR as a starting sequence and has a corresponding mutation site, wherein the dihydrodaidzein reductase AeDHDR is derived from AdleCRzia equaliforns, and the amino acid sequence of the dihydrodaidzein reductase AeDHDR is shown as SEQ ID NO: 2. The invention also discloses a coding gene, a carrier and a bioengineering bacterium of the dihydrodaidzein reductase mutant and a method for synthesizing S-equol. The method has the advantages of high enzyme activity and high S-equol yield.

To manufacture equol simply and reliably. [Solution] The method comprises at least the steps of: dissolving soy germ isoflavones containing daidzin or daidzein, β-glucosidase, and calcined coral calcium hydrogen powder that generates negative hydrogen ions in water to create an aqueous solution of hydrogen-dissolved soy germ isoflavones; mixing the aqueous solution of hydrogen-dissolved soy germ isoflavones for a predetermined time under predetermined temperature and pressure conditions and allowing it to stand; and concentrating equol using an activated carbon filter made of Ina Akamatsu Myotan with a specific surface area of ​​400 m² / g, wherein the temperature conditions are 30°C to 60°C, the pressure conditions are 1 atmosphere to 5 atmospheres, the predetermined time is 9 hours to 15 hours, and the aqueous solution concentrated using the activated carbon filter contains 0.26 g of equol per 100 g.

The present invention is to provide at least a production method of a composition containing equol and / or equol derivative, which does not undergo browning even when heated as it is or in the presence of an additional amino acid or the like. The problem is solved by a production method of a composition including the following (a) process, (b1) process and / or (b2) process, and (c) process. (a) Process of generating glucose and isoflavone aglycone from isoflavone glycoside; (b1) Process of causing a microorganism having equol production ability to produce equol from the isoflavone aglycone; (b2) Process of causing a microorganism having equol derivative production ability to produce equol derivative from the isoflavone aglycone; and (c) Process of decomposing the glucose so that the content of the glucose in the composition is 0 g / L or more and less than 2.0 g / L, or 30 g / kg or less relative to the amount of solid components of the composition.

The application discloses a kind of complex fermentation inoculant for improving equol production, fermentation liquor and application thereof, belong to microbial fermentation technical field.The complex fermentation inoculant of the application, streptococcus thermophilus BLCC2-0025 and lactococcus lactis MP1001 have high β-glucosidase activity, and low activity glycoside form is converted into high activity daidzein;Salivary lactobacillus LS1101 and lactobacillus gregius 0010 have the activity of further converting daidzein into equol;Four strains of bacteria are used in combination, which can synergistically improve the content of equol.The fermentation liquor prepared by fermenting pueraria extract with the complex fermentation inoculant of the application can target regulate intestine-ovary axis, significantly improve the reproductive function of POF mice, relieve ovarian oxidative stress and accurately regulate intestinal flora balance, providing a safe and effective preparation and application scheme for non-hormone intervention of premature ovarian failure.

The invention discloses a glycosyl transferase combined mutant and application thereof, and aims to solve the problems that the existing wild PlUGT43 and F196Y single-point mutants thereof have narrow substrate spectrums and cannot efficiently catalyze a plurality of isoflavone derivatives with large structural differences to perform C-glycosylation reaction. The glycosyl transferase combination mutant provided by the invention is a protein which simultaneously contains five mutated sites, namely T81S, N186S, L187A, F196Y and S310P, on the basis of a wild PlUGT43 amino acid sequence as shown in SEQ ID NO.3. The glycosyl transferase combination mutant provided by the invention is a protein which is obtained by mutating five sites, namely T81S, N186S, L187A, F196Y and S310P. Compared with a wild type and an F196Y single-site mutant, the combined mutant has the advantages that the catalytic activity on classical substrates such as daidzein is improved, and efficient C-glycosylation on various substrates such as soybean dihydroaglycone, equol and resveratrol which are difficult to catalyze or extremely low in catalytic efficiency is also realized; the application potential of the glycosyl transferase in the aspect of synthesis of diversified natural products is improved.

The present invention relates to: an intestinal microbiome biomarker composition for distinguishing equol producers; and use thereof. Intestinal microbiome biomarkers are differently expressed between equol producers and non-producers, and thus equol producers can be distinguished by confirming the expression of the biomarkers. Therefore, it is expected that the intestinal microbiome biomarkers for distinguishing equol producers, of the present invention, can be used to simply distinguish between equol producers and non-producers.

This invention provides *Lactobacillus gasseri* and its application in the preparation of phytoestrogens, relating to the field of biofermentation technology. The *Lactobacillus gasseri* is *Lactobacillus gasseri* (…). Lactobacillus gasseri The strain, KMHD3-7519, registered with the China General Microbiological Culture Collection Center (CGMCC) under number CGMCC No. 32351, can increase the content of phytoestrogens in plant extracts. It promotes the conversion of daidzein to daidzein in plant extracts and simultaneously converts daidzein partially to equol, thus increasing the total amount of phytoestrogens in the extract. This invention provides a probiotic capable of simultaneously promoting the conversion of two phytoestrogens, which can be used to produce daidzein, or equol, or simultaneously increase both daidzein and equol, with broad application prospects.

To provide a new lactic acid bacterium and its use.SOLUTION: The features of the present invention for solving the above problems are as follows. It is characterized in that it can be used for various health-promoting applications using lactic acid bacteria Lacticaseibacillusparacaseisp. Shidare (accession number NITEABP-04138). Specifically, this lactic acid bacterium is characterized by exhibiting various effects such as promotion of production of IgA, IL-10, IL-12, and serotonin, normalization of stool shape and improvement of bowel movement, improvement of feeling of incomplete evacuation, adjustment of intestinal environment, immunoregulatory action, promotion of equol production, and further, promotion of collagen gene and hyaluronic acid gene expression, and EMT suppression.SELECTED DRAWING: None

To provide a food composition containing equol and an organic acid and having improved flavor, especially aroma.SOLUTION: The food composition contains an organic acid and equol, particularly at least one organic acid selected from the group consisting of carbonic acid, hydrogen carbonate, citric acid, lactic acid, phosphoric acid, gluconic acid, acetic acid, malic acid, orotic acid, ammonium salts thereof, alkali metal salts thereof, alkaline earth metal salts thereof, and chelates thereof, and equol.SELECTED DRAWING: None

This invention discloses an S-estrol composition for delaying ovarian aging and its uses, relating to the fields of biomedicine and health products. The S-estrol composition for delaying ovarian aging comprises, by weight, the following components: 1-5 parts S-estrol, 2-8 parts soy isoflavones, 3-10 parts coenzyme Q10, 2-6 parts vitamin E, 4-12 parts vitamin C, 0.01-0.05 parts folic acid, 0.1-0.3 parts zinc source, 0.5-1.5 parts anti-aging protective agent, 50-80 parts carrier, and 10-15 parts purified water. This invention uses high-purity S-estrol as the core, combined with soy isoflavones, coenzyme Q10 and a variety of antioxidant nutrients in a scientific formulation to form a synergistic system for estrogen receptor signal regulation and antioxidant defense. By constructing a complex antioxidant network and introducing novel anti-aging protectants for synergistic effect, the activity of antioxidant enzymes tends to increase and the level of lipid peroxidation tends to decrease, thereby improving the oxidative stress state in ovarian cells as a whole.

The application discloses a tetrahedral framework nucleic acid complex loaded with equol and application of the complex in preparation of a medicine for relieving fatty liver disease. The complex is obtained by stable combination of tetrahedral framework nucleic acid and equol through hydrogen bond and hydrophobic interaction; the equol is loaded on the tetrahedral framework nucleic acid structure, and can be slowly released, so that the bioavailability of the equol is improved, and the problems of poor water solubility and low stability of the equol are effectively overcome. Meanwhile, the complex can inhibit lipid accumulation in HepG2 cells, relieve lipid deposition of liver cells, and reduce accumulation of TG and T-CHO in cells, and can be used for relieving fatty liver, and preparing more and more efficient fatty liver treatment medicines, and has wide application potential in intervention of lipid metabolism disorder and related metabolic diseases.

This invention discloses an Equoluxe multivitamin tablet containing a natural hormone regulator and its preparation process, belonging to the field of pharmaceutical technology. The invention comprises the following formula in parts by weight: 80-100 parts soybean extract, 20-55 parts plant-based lactic acid bacteria, 5-10 parts ginseng extract, 80 parts ginger extract, and 10-30 parts excipients. This invention, through a specific combination, works synergistically to promote estrogen secretion in women, enhance ovarian function, and maintain hormonal balance. By microencapsulating the plant-based lactic acid bacteria during pretreatment, this invention significantly improves the activity retention rate during tableting and storage, achieving an activity retention rate of over 87% after 6 months under accelerated conditions, thus solving the technical problem of poor stability in probiotic products. This invention employs a gradient mixing and low-temperature pressing process to avoid local aggregation of highly active ingredients and high-temperature inactivation, ensuring the uniformity of content and bioavailability of key components such as equoluxone and lactic acid bacteria in the tablets.

Provided is an equol-containing composition in which bitterness is suppressed, and in particular, an equol-containing composition in which bitterness is suppressed and which is completely or equivalently unrestricted in food applications. The present invention provides an equol-containing composition comprising at least one masking agent selected from the group consisting of thaumatin and a siraitia grosvenorii extract, and an equol-containing substance, and if necessary, at least one sweetening agent selected from the group consisting of aspartame, neotame, Advantame, acesulfame, stevioside, curculiginine, molinin, monatin, synsepalum dulcificum protein, and sweet clostridium.

The present disclosure addresses the problem of providing a composition that contains 5-hydroxyequol and that can be used in a new application. The present disclosure also addresses another problem of providing a method for extending healthy life expectancy, the method comprising bringing 5-hydroxyequol into contact with a subject.　The present disclosure provides a composition for extending healthy life expectancy, the composition containing 5-hydroxyequol. Also provided is a method for producing a composition containing 5-hydroxyequol, the method comprising producing 5-hydroxyequol from genistein through fermentation. The present disclosure also provides a method for extending healthy life expectancy, the method comprising bringing 5-hydroxyequol into contact with a subject.

This invention belongs to the field of functional food technology, specifically relating to a sleep-aiding composition containing γ-aminobutyric acid (GABA) and its application. The sleep-aiding composition comprises: 2 to 8 parts of fermented soybean extract; 3 to 10 parts of oyster oligopeptide powder; 0.5 to 5 parts of GABA; 1 to 4 parts of Atractylodes macrocephala volatile oil β-cyclodextrin inclusion complex; and 1 to 4 parts of Acanthopanax senticosus extract. This composition is used in the preparation of products with sleep-improving effects. This invention utilizes a two-stage fermentation process to pre-convert soybean isoflavones to estrol and enrich GABA, combined with targeted enzymatic hydrolysis membrane separation to enrich taurine and zinc in oyster oligopeptides to maintain GABA-A receptor sensitivity. The addition of Atractylodes macrocephala volatile oil β-cyclodextrin inclusion complex improves water solubility and stability, achieving stable sleep-aiding effects and minimizing individual differences, while also promoting growth and development.

The invention discloses a mutant for efficiently synthesizing S-equol and a whole-cell transformation system. Specifically, the invention provides a DZNR mutant for catalytic production of S-equol, and the catalytic activity of the DZNR mutant is remarkably improved compared with that of wild type DZNR. By using the engineering bacteria containing the mutant, the yield of S-equol can be obviously improved. Meanwhile, an EcN whole-cell transformation system is constructed and can be used for safely and efficiently generating S-equol.

The present invention pertains to a new lactic acid bacterium Lacticaseibacillus paracasei strain Shidare (accession number: NITE BP -04138). The lactic acid bacterium can be used for various health promotion applications, and specifically exhibits a wide variety of effects such as promotion of production of IgA, IL -10, IL -12, and serotonin, normalization of stool shape, improvement of bowel movement, improvement of stool-remaining feeling, regulation of intestinal environment, immunoregulation action, equol production promotion, and collagen gene and hyaluronic acid gene expression promotion.

The invention discloses a genetically engineered bacterium for producing (S)-equol and application of the genetically engineered bacterium, and belongs to the technical field of genetic engineering and synthetic biology. The method comprises the following steps: co-expressing production genes of (S)-equol in escherichia coli: daidzein reductase gene Acdznr, dihydrodaidzein racemase gene Lgddrc, tetrahydrodaidzein reductase gene Sithdr and dihydrodaidzein reductase gene Sidhdr to construct a multi-enzyme co-expression system, and meanwhile, carrying out overexpression on NADPH (Nicotinamide Adenine Dinucleotide Phosphate) to regenerate glucose-6-phosphate dehydrogenase gene E.colizwf, so as to obtain the (S)-equol. Through a strategy of enhancing NADPH synthesis and reducing NADPH consumption, a forward reaction of equol generation is enhanced, and a genetically engineered bacterium for producing (S)-equol is formed. The highest concentration of (S)-equol can be 360 mg / L through fermentation production in a shake flask, and 2.2 g / L of (S)-equol is generated through fermentation for 63 h in a 5L fermentation tank.

This invention provides a novel phosphorylated equol with enhanced solubility in water. [Solution] Phosphorylated equol represented by formula (1) or a pharmaceutically acceptable salt thereof. TIFF2026063030000006.tif34170 (wherein R1 is a phosphate group and R2 is a hydroxyl group)

The present invention relates to a method for screening for an equol producer by using personalized pharmaceutical meta-analytical screening (PMAS) technology. According to the method of the present invention, soybean isoflavone bioconversion by an intestinal microorganism is analyzed such that whether the microorganism is an equol producer can be determined. Therefore, by screening the metabolic conversion ability of the main components of soybeans, the difference in effects of individual functional materials can be easily determined.

The application discloses a kind of complex fermentation inoculant for improving equol production, fermentation liquor and application thereof, belong to microbial fermentation technical field.The complex fermentation inoculant of the application, streptococcus thermophilus BLCC2-0025 and lactococcus lactis MP1001 have high β-glucosidase activity, and low activity glycoside form is converted into high activity daidzein;Salivary lactobacillus LS1101 and lactobacillus gregius 0010 have the activity of further converting daidzein into equol;Four strains of bacteria are used in combination, which can synergistically improve the content of equol.The fermentation liquor prepared by fermenting pueraria extract with the complex fermentation inoculant of the application can target regulate intestine-ovary axis, significantly improve the reproductive function of POF mice, relieve ovarian oxidative stress and accurately regulate intestinal flora balance, providing a safe and effective preparation and application scheme for non-hormone intervention of premature ovarian failure.

This invention discloses a daidzein reductase mutant and its application in the preparation of (S)-equorol. The amino acid sequence of the daidzein reductase mutant I53G / Q148M / Y182F is the amino acid sequence shown in SEQ ID NO: 2, with isoleucine at position 53 mutated to glycine, glutamine at position 148 mutated to methionine, and tyrosine at position 182 mutated to phenylalanine. The nucleotide sequence of the daidzein reductase mutant gene is shown in SEQ ID NO: 3. This gene was introduced into *E. coli* to obtain a recombinant genetically engineered bacterium containing this gene, enabling the preparation of a recombinant daidzein reductase mutant for the highly active and stereoselective reduction of daidzein to dihydrodaidzein, laying the foundation for the subsequent efficient bioprocessing of (S)-equorol.

The present invention relates to the field of microbiology and biotechnology, in particular, the present invention relates to an engineered bacterium, cultures, dietary supplements and pharmaceutical compositions comprising the same, and their use in the manufacture of a medicament. The present invention also provides methods of culturing the engineered bacterium and methods of producing equol.

The present application relates to a method for converting daidzein into equol by engineering yeast and its application. Specifically, the present application provides an engineered yeast and a method for converting daidzein into equol by using the engineered yeast. The yeast strain is genetically engineered to have the ability to efficiently catalyze the conversion of daidzein into equol. In a 10L fermentation system, 10g / L of daidzein can be converted into 5.65g / L of equol, and the conversion rate is much higher than the known methods in the art. The method of the present application can efficiently and environmentally synthesize equol, and the process is simple and suitable for industrial large-scale production.

Problem: To provide an oral agent capable of maintaining the health of mammary gland tissue.Solution: An agent for maintaining health of mammary gland tissue is characterized by containing GABA as an active ingredient. In addition, the combined use of GABA and equol can enhance the effect of maintaining the health of mammary gland tissue and the effect of preventing early stage breast cancer by inhibiting dysplasia in mammary gland tissue.

The invention provides an application of a burdock extract and a composition thereof in preparation of a product for preventing, delaying or improving equol deficiency related diseases or symptoms, relates to the technical field of biology, and particularly relates to an application of a burdock extract in preparation of a product for preventing, delaying or improving equol deficiency related diseases or symptoms. In-vitro fermentation experiments prove that in a fermentation system containing daidzein and human intestinal flora, the burdock extract is added, so that the generation of equol can be remarkably promoted, and the yield of the burdock extract is remarkably improved compared with that of a positive control group only added with daidzein. The burdock extract is safe and natural in raw material and free of toxic and side effects, provides an effective intervention strategy for promoting human intestinal equol, and can be used for developing and preparing medicines, foods or health care products for preventing, delaying or improving equol deficiency related diseases or symptoms (such as climacteric syndrome, osteoporosis and hormone-dependent cancer risks).

The invention provides a composition for improving an ovarian function as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from urolithin and S-equol. The mass ratio of the urolithin to the S-equol in the composition is (1-30): 1. The composition can significantly improve the ovarian function and repair ovarian structure damage, and through the synergistic effect of urolithin and S-equol, the composition can significantly improve the survival rate of zebra fish oocyte, effectively increase the ovary weight index, reverse cisplatin-induced ovarian atrophy, and inhibit activation of apoptosis pathway key molecule Caspase-3. And the composition can improve the fertility, reduce the problem of poor development of the offspring, and realize dual improvement of the fertility and the health of the offspring.